Jubilant Ingrevia Ltd

Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Ingrevia Ltd

₹ 623 0.98%
12 Jun - close price
jubilantingrevia.com BSE: 543271 NSE: JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider.

Website BSE NSE
  • Market Cap ₹ 9,930 Cr.
  • Current Price ₹ 623
  • High / Low ₹ 852 / 535
  • Stock P/E 35.8
  • Book Value ₹ 166
  • Dividend Yield 0.80 %
  • ROCE 12.4 %
  • ROE 10.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 31.4%
  • Company's working capital requirements have reduced from 13.5 days to 10.2 days

Cons

  • Stock is trading at 3.76 times its book value
  • Company has a low return on equity of 9.99% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.25%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE 500 Nifty 500 Nifty500 Shariah BSE Commodities BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,061 1,031 1,003 917 1,037 969 1,005 995 972 973 1,054 1,018 1,093
974 917 882 843 943 881 878 864 844 852 953 906 956
Operating Profit 87 114 121 74 94 88 128 131 128 121 101 112 138
OPM % 8% 11% 12% 8% 9% 9% 13% 13% 13% 12% 10% 11% 13%
8 10 8 8 10 9 9 27 36 11 11 20 46
Interest 10 15 16 18 17 17 17 15 16 15 14 15 13
Depreciation 29 32 33 34 35 36 37 37 37 38 39 42 43
Profit before tax 56 77 80 30 52 44 82 106 111 79 59 75 128
Tax % 32% 29% 28% 36% 41% 26% 27% 24% 19% 26% 26% 21% 18%
39 55 57 19 31 33 60 81 90 59 44 60 105
EPS in Rs 2.43 3.44 3.60 1.21 1.94 2.06 3.78 5.06 5.64 3.70 2.76 3.75 6.61
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 669 4,860 4,560 3,987 3,941 4,138
0 572 4,039 4,064 3,578 3,466 3,666
Operating Profit -0 97 821 496 409 475 472
OPM % 14% 17% 11% 10% 12% 11%
0 -10 21 30 29 81 87
Interest 0 9 46 38 66 65 57
Depreciation 0 21 120 120 133 147 161
Profit before tax -0 56 675 368 239 343 342
Tax % 0% 31% 33% 31% 32% 23% 22%
-0 39 452 253 162 263 268
EPS in Rs -3.40 2.42 28.39 15.91 10.20 16.54 16.82
Dividend Payout % 0% 14% 18% 31% 49% 30% 15%
Compounded Sales Growth
10 Years: %
5 Years: 44%
3 Years: -3%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: 42%
3 Years: 3%
TTM: 5%
Stock Price CAGR
10 Years: %
5 Years: 2%
3 Years: 12%
1 Year: -21%
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 10%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.05 16 16 16 16 16 16
Reserves -0 1,560 1,967 2,143 2,231 2,425 2,624
0 782 469 645 870 825 747
0 882 1,200 1,255 1,223 1,255 1,337
Total Liabilities 0 3,240 3,652 4,058 4,340 4,521 4,723
0 1,727 1,728 1,775 2,292 2,335 2,366
CWIP 0 65 167 477 181 197 139
Investments 0 135 139 172 297 310 327
0 1,313 1,619 1,635 1,571 1,679 1,892
Total Assets 0 3,240 3,652 4,058 4,340 4,521 4,723

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 104 587 446 394 441 462
0 32 -221 -475 -464 -211 -108
0 -70 -410 33 64 -208 -230
Net Cash Flow 0 66 -44 3 -6 22 124
Free Cash Flow 0 77 365 3 55 239 335
CFO/OP 0% 119% 85% 104% 104% 108% 116%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 262 44 40 52 53 61
Inventory Days 490 97 127 132 141 116
Days Payable 649 101 117 129 139 139
Cash Conversion Cycle 103 40 50 55 55 38
Working Capital Days 179 32 23 12 18 10
ROCE % 7% 30% 16% 11% 13% 12%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Customer Base Size
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Manufacturing Plants
Count
Number of Products in Portfolio
Count
Number of Pyridine Derivatives with Global #1 Position
Count
Renewable Power Share in Total Consumption
%
Workforce Strength
Employees
New Molecules Won in last 12 months
Count
Active CDMO Opportunity Funnel
Count
R&D Pipeline (Products under development)
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 45.22% 45.22% 45.22% 45.22%
6.15% 6.30% 6.35% 6.58% 6.55% 7.22% 6.89% 7.12% 6.96% 5.96% 6.15% 6.49%
6.72% 9.18% 11.17% 13.60% 14.07% 15.47% 15.99% 15.91% 21.81% 23.04% 24.00% 24.76%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.02%
34.83% 32.22% 30.17% 27.53% 27.10% 25.09% 24.90% 24.76% 25.30% 24.94% 23.80% 22.53%
0.82% 0.82% 0.82% 0.81% 0.81% 0.77% 0.74% 0.73% 0.72% 0.82% 0.80% 0.98%
No. of Shareholders 1,86,2941,73,5331,62,2021,50,3881,42,7361,25,3671,24,8301,20,4061,23,7481,25,7491,17,5291,12,696

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls